Prevention of chronic cerebral vasospasm in dogs with milrinone

Neurosurgery

Volumn 40, Issue 2, 1997, Pages 354-363

  Khajavi, Kaveh ^a   Ayzman, Igor ^b   Shearer, David ^b   Jones, Stephen C ^b   Levy, Jerrold H ^c   Prayson, Richard A ^b   Skibinski, Christine I ^b   Hahn, Joseph F ^b   Chyatte, Douglas ^b  

^a WILLIAM BEAUMONT ARMY MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Canine model; Cerebral vasospasm; Milrinone; Phosphodiesterase inhibitors; Subarachnoid hemorrhage

Indexed keywords

MILRINONE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV;

ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CISTERNA MAGNA; CONTROLLED STUDY; DOG; DRUG EFFICACY; HEART OUTPUT; HEMODYNAMIC MONITORING; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; SECOND MESSENGER; SUBARACHNOID HEMORRHAGE; SUBCUTANEOUS DRUG ADMINISTRATION; VASOSPASM;

ANIMALS; CEREBRAL ANGIOGRAPHY; DOGS; HEMODYNAMIC PROCESSES; ISCHEMIC ATTACK, TRANSIENT; MILRINONE; PHOSPHODIESTERASE INHIBITORS; PYRIDONES; SUBARACHNOID HEMORRHAGE; VASODILATOR AGENTS;

EID: 0031030182     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199702000-00025     Document Type: Article

References (48)

1. Alousi AA, Canter JM, Montenare MJ, Fort DJ, Ferrari RA: Cardiotonic activity of milrinone, a new and potent cardiac bipyridine, on the normal and failing heart of experimental animals. J Cardiovasc Pharmacol 5:792-803, 1983.
2. Alousi AA, Johnson DC: Pharmacology of the bipyridines amrinone and milrinone. Circulation 73[Suppl III]:10-24, 1986.
3. Alousi AA, Stankus GP, Stuart JC, Walton LH: Characterization of the cardiotonic effects of milrinone, a new and potent cardiac bipyridine, on isolated tissues from several animal species. J Cardiovasc Pharmacol 5:804-811, 1983.
4. Anderson JL: Hemodynamic and clinical benefits with intravenous milrinone in severe chronic heart failure: Results of a multicenter study in the United States. Am Heart J 121:1956-1964, 1991.
5. Awad IA, Carter LP, Spetzler RF, Medina M, Williams FC Jr: Clinical vasospasm after subarachnoid hemorrhage: Response to hypervolemic hemodilution and arterial hypertension. Stroke 18: 365-372, 1987.
6. 2 synthesis: An in vitro study. Thrombosis Res 71:227-236, 1993.
7. Beavo JA, Reifsnyder DH: Primary sequence of cyclic nucleotide phosphodiesterase isoenzymes and the design of selective inhibitors. Trends Pharmacol Sci 11:150-155, 1990.
8. Benotti JR, Lesko LJ, McCue JE, Alpert JS: Pharmacokinetics and pharmacodynamics of milrinone in chronic congestive heart failure. Am J Cardiol 56:685-689, 1985.
9. Biddle TL, Benotti JR, Creager MA, Faxon DP, Firth BG, Fitzpatrick PG, Konstam MA, Krebs C, Walton L, Kersner RP: Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy. Am J Cardiol 59:1345-1350, 1987.
10. Borow KM, Come PC, Neumann A, Baim DS, Braunwald E, Grossman W: Physiologic assessment of the inotropic, vasodilator, and afterload reducing effects of milrinone in subjects without cardiac disease. Am J Cardiol 55:1204-1209, 1985.
11. 2+ monitored by aequorin in adenosine mediated smooth muscle relaxation. Am J Physiol 248:H109-H117, 1985.
12. Colucci WS, Wright RF, Jaski BF, Fifer MA, Braunwald E: Milrinone and dobutamine in severe heart failure: Differing hemodynamic effects and individual patient responsiveness. Circulation 73[Suppl III]:175-182, 1986.
13. Dragunow M: Adenosine: The brain's natural anticonvulsants. Trends Pharmacol Sci 1:128-130, 1986.
14. Edelson J, Koss RF, Barker JF, Park GB: High performance liquid chromatographic analysis of milrinone in plasma and urine: Intravenous pharmacokinetics in the dog. J Chromatogr 276:456-462, 1983.
15. Findlay JM, MacDonald RL, Weir BKA: Current concepts of pathophysiology and management of cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Cerebrovasc Brain Metab Rev 3:336-361, 1991.
16. Flamm ES, Ransohoff J: Treatment of cerebral vasospasm by control of cyclic adenosine monophosphate. Surg Neurol 6:223-226, 1976.
17. Fleischer AS, Raggio JF, Tindall GT: Aminophylline and isoproterenol in the treatment of cerebral vasospasm. Surg Neurol 8:117-121, 1977.
18. Goldberg ND, Haddox MK, Hartle DK, Hadden JW: The biological role of 3′,5′-guanosine monophosphate: Pharmacology and the future of man Proc Int Congr Pharmacol 5:146-169, 1973.
19. Goldstein RA, Geraci SA, Gray EL, Rinkenberger RL, Dougherty AH, Naccarelli GV: Electrophysiologic effects of milrinone in patients with congestive heart failure. Am J Cardiol 57:624-628, 1986.
20. Grose RM, Strain JE, Bergman MJ, McGinnis J, Greenberg MA, Lejementel TH: Milrinone vs. dobutamine: A comparative study. Circulation 70[Suppl II]:11, 1984.
21. Harbinson RG, Lippton HL, Hyman AL, Kadowitz TJ: Pulmonary vascular actions of amrinone and milrinone. Circulation 70[Suppl II]:182, 1984 (abstr).
22. Harris AL, Grant AM, Silver PJ, Evans DB, Alousi AA: Differential vasorelaxant effects of milrinone and amrinone on contractile responses of canine coronary, cerebral, and renal arteries. J Cardiovasc Pharmacol 13:238-244, 1989.
23. Harrison SA, Reifsnyder DH, Gallis B, Cadd GG, Beavo JA: Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: A receptor for new cardiac drugs. Mol Pharmacol 29:506-514, 1986.
24. Hijdra A, Braakman R, van Gijn J, Vermeulen M, van Crevel H: Aneurysmal subarachnoid hemorrhage: Complications and outcome in a hospital population. Stroke 18:1061-1067, 1989.
25. Honerjager P: Pharmacology of bipyridine phosphodiesterase III inhibitors. Am Heart J 121:1939-1944, 1991.
26. Ignarro LJ, Kadowitz PJ: The pharmacologic and physiologic role of cyclic GMP in vascular smooth muscle relaxation. Annu Rev Pharmacol Toxicol 25:171-191, 1985.
27. 2+ uptake by human platelets. Eur J Pharmacol 245:67-73, 1993.
28. Kassell NF, Peerless SJ, Durward QJ, Beck DW, Drake CG, Adams HP: Treatment of ischemic deficits from vasospasm with intravascular volume expansion and induced arterial hypertension. Neurosurgery 11:337-343, 1982.
29. Katsuki S, Arnold WP, Murad F: Effects of sodium nitroprusside, nitroglycerin, and sodium azide on levels of cyclic nucleotides and mechanical activity on various tissues. J Cyclic Nucleotide Res 3:239-247, 1977.
30. Kauffman RF, Schenck KW, Utterback BG, Crowe VG, Cohen ML: In vitro vascular relaxation by new inotropic agents: Relationship to phosphodiesterase inhibition and cyclic nucleotides. J Pharmacol Exp Ther 242:864-872, 1987.
31. Lebedinsky Y, Nordstrom ST, Aschoff SE, Kapples JF: Cardiotonic and coronary vasodilator responses to milrinone, forskolin, and analog P87-7692 in the anesthetized dog. J Cardiovasc Pharmacol 19:779-789, 1992.
32. Lejementel TH, Maskin CS, Chadwick B, Sonnblick EH: Hemodynamic effects of intravenous and oral milrinone in patients with chronic heart failure, in Brawnwald E, Sonnenblick EH, Chakrin LW, Schwartz PR (eds): Milrinone: Investigation of New Inotropic Therapy for Congestive Heart Failure. New York, Raven Press, 1984, pp 133-141.
33. Levy ML, Rabb CH, Zelman V, Giannotta SL: Cardiac performance enhancement from dobutamine in patients refractory to hypovolemic therapy for cerebral vasospasm. J Neurosurg 79: 494-499, 1993.
34. Lindgren S, Anderson KE, Beifrage P, Dergerman E, Manganiello VC: Relaxant effects of the selective phosphodiesterase inhibitors milrinone and OPC 3911 on isolated human mesenteric vessels. Pharmacol Toxicol 64:440-445, 1989.
35. Mager G, Klocke RK, Adelgunde K, Kux A, Hopp HW, Hilger HH: Phosphodiesterase III inhibition or adrenoreceptor stimulation: Milrinone as an alternative to dobutamine in the treatment of severe heart failure. Am Heart J 121:1974-1983, 1991.
36. Monrad ES, Baim DS, Smith HS, Lanoue AS, Silverman KJ, Gervino EV, Grossman W: Milrinone, dobutamine, and nitroprusside: Comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure. Circulation 73[Suppl III]:168-174, 1986.
37. Morgan JP, Gwathmey JK, DeFoe TT, Morgan KG: The effects of amrinone and related drugs on intracellular calcium in isolated mammalian cardiac and vascular smooth muscle. Circulation 73[Suppl III]:65-77, 1986.
38. Muir AL, Nolan J: Modulation of venous tone in heart failure. Am Heart J 121:1948-1950, 1991.
39. Nakatsu K, Diamond J: Role of cGMP in relaxation of vascular and other smooth muscle. Can J Physiol Pharmacol 167:251-262, 1988.
40. 2+ -ATPase and cAMP phosphodiesterase activity by milrinone. Drug Dev Res 19:435-442, 1990.
41. Pickard JD, Murray GD, Illingworth R, Shaw MD, Teasdale GM, Foy PM, Humphrey PR, Lang DA, Nelson R, Richards P, Sinar J, Bailey S, Skene A: Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid hemorrhage: British Aneurysm Nimodipine Trial. Br Med J 298:636-642, 1989.
42. Shimoda M, Oda S, Tsugane R, Sato O: Intracranial complications of hypervolemic therapy in patients with a delayed ischemic deficit attributed to vasospasm. J Neurosurg 78:423-429, 1993.
43. m cyclic AMP phosphodiesterase and activation of the cyclic AMP system in vascular smooth muscle by milrinone. J Pharmacol Exp Ther 247:34-42, 1988.
44. Strada SJ, Kithas PA, Whalin ME, Thompson WJ: Molecular properties of cyclic nucleotide phosphodiesterase isoenzymes. Adv Exp Med Biol 255:409-423, 1989.
45. Sundt TM, Szurszewski J, Sharbrough FW: Physiological considerations for the management of vasospasm. Surg Neurol 7:250-267, 1977.
46. van Dellen RG: Theophylline: Practical application of new knowledge. Mayo Clin Proc 54:733-745, 1979.
47. Varsos VG, Liszczak TM, Han DH, Kistler JP, Vielma J, Black PMcL, Heros RC, Zervas NT: Delayed cerebral vasospasm is not reversible by aminophylline, nifedipine, or papaverine in a "two-hemorrhage" canine model. J Neurosurg 58:11-17, 1983.
48. Weishaar RE, Burrows SD, Kobylarz DC, Quade MM, Evans DB: Multiple molecular forms of cyclic phosphodiesterase in cardiac and smooth muscle and in platelets. Biochem Pharmacol 5:787-800, 1986.